Platelet phenotype changes associated with breast cancer and its treatment

References

• Lal I, Dittus K, Holmes CE. Platelets, coagulation and fibrinolysis in breast cancer progression. Breast Cancer Res 2013;15(4):207.
   PubMed Web of Science ®Google Scholar
• Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011;9(2):237–249.
   PubMed Web of Science ®Google Scholar
• Caine GJ, Lip GY, Blann AD. Platelet-derived VEGF, Flt-1, angiopoietin-1 and P-selectin in breast and prostate cancer: Further evidence for a role of platelets in tumour angiogenesis. Ann Med 2004;36(4):273–277.
   PubMed Web of Science ®Google Scholar
• Ferriere JP, Bernard D, Legros M, Chassagne J, Chollet P, Gaillard G, Plagne R. beta-Thromboglobulin in patients with breast cancer. Am J Hematol 1985;19(1):47–53.
   PubMed Web of Science ®Google Scholar
• Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC, Schmid M, Smola MG, Stierer M, Tausch C and others. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003;89(6):1098–1106.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Francis CW, Culakova E, Lyman GH. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 2005;104(12):2822–2829.
   PubMed Web of Science ®Google Scholar
• Holmes CE, Huang JC, Pace TR, Howard AB, Muss HB. Tamoxifen and aromatase inhibitors differentially affect vascular endothelial growth factor and endostatin levels in women with breast cancer. Clinical Cancer Research 2008;14(10):3070–3076.
   PubMed Web of Science ®Google Scholar
• Kedzierska M, Czernek U, Szydlowska-Pazera K, Potemski P, Piekarski J, Jeziorski A, Olas B. The changes of blood platelet activation in breast cancer patients before surgery, after surgery, and in various phases of the chemotherapy. Platelets 2013;24(6):462–468.
   PubMed Web of Science ®Google Scholar
• Kedzierska M, Olas B, Wachowicz B, Glowacki R, Bald E, Czernek U, Szydlowska-Pazera K, Potemski P, Piekarski J, Jeziorski A. Effects of the commercial extract of aronia on oxidative stress in blood platelets isolated from breast cancer patients after the surgery and various phases of the chemotherapy. Fitoterapia 2012;83(2):310–317.
   PubMed Web of Science ®Google Scholar
• Hojima Y, Pierce JV, Pisano JJ. Plant inhibitors of serine proteinases: Hageman factor fragment, kallikreins, plasmin, thrombin, factor Xa, trypsin, and chymotrypsin. Thromb Res 1980;20(2):163–171.
   PubMed Web of Science ®Google Scholar
• Kahn ML, Zheng YW, Huang W, Bigornia V, Zeng D, Moff S, Farese RV, Jr., Tam C, Coughlin SR. A dual thrombin receptor system for platelet activation. Nature 1998;394(6694):690–694.
   PubMed Web of Science ®Google Scholar
• Faruqi TR, Weiss EJ, Shapiro MJ, Huang W, Coughlin SR. Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J Biol Chem 2000;275(26):19728–19734.
   Google Scholar
• Polgar J, Clemetson JM, Kehrel BE, Wiedemann M, Magnenat EM, Wells TN, Clemetson KJ. Platelet activation and signal transduction by convulxin, a C-type lectin from Crotalus durissus terrificus (tropical rattlesnake) venom via the p62/GPVI collagen receptor. J Biol Chem 1997;272(21):13576–13583.
   PubMed Web of Science ®Google Scholar
• Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ and others. Vascular endothelial growth factor (VEGF) in breast cancer: Comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res 2000;60(11):2898–2905.
   PubMed Web of Science ®Google Scholar
• Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res 2009;69(19):7775–7783.
   PubMed Web of Science ®Google Scholar
• Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell 2011;20(5):576–590.
   PubMed Web of Science ®Google Scholar
• Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care 2009;32(4):525–527.
   PubMed Web of Science ®Google Scholar
• Watala C, Boncer M, Golanski J, Koziolkiewcz W, Trojanowski Z, Walkowiak B. Platelet membrane lipid fluidity and intraplatelet calcium mobilization in type 2 diabetes mellitus. Eur J Haematol 1998;61(5):319–326.
   PubMed Web of Science ®Google Scholar
• Kutti J, Wadenvik H, Henestam B, Stenstrom G. Evaluation of platelet reactivity in diabetes mellitus. Acta Med Scand 1986;219(2):195–199.
   PubMedGoogle Scholar
• Keating FK, Sobel BE, Schneider DJ. Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes mellitus. Am J Cardiol 2003;92(11):1362–1365.
   PubMed Web of Science ®Google Scholar
• Sagel J, Colwell JA, Crook L, Laimins M. Increased platelet aggregation in early diabetus mellitus. Ann Intern Med 1975;82(6):733–738.
   PubMed Web of Science ®Google Scholar
• Winocour PD, Bryszewska M, Watala C, Rand ML, Epand RM, Kinlough-Rathbone RL, Packham MA, Mustard JF. Reduced membrane fluidity in platelets from diabetic patients. Diabetes 1990;39(2):241–244.
   PubMed Web of Science ®Google Scholar
• Shukla SD, Paul A, Klachko DM. Hypersensitivity of diabetic human platelets to platelet activating factor. Thromb Res 1992;66(2–3):239–246.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Sabate M, Jimenez-Quevedo P, Costa MA, Palazuelos J, Hernandez-Antolin R, Moreno R, Escaned J, Alfonso F and others. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50(16):1541–1547.
   PubMed Web of Science ®Google Scholar
• Jung JH, Tantry US, Gurbel PA, Jeong YH. Current antiplatelet treatment strategy in patients with diabetes mellitus. Diabetes Metab J 2015;39(2):95–113.
   PubMed Web of Science ®Google Scholar
• Wiesner T, Bugl S, Mayer F, Hartmann JT, Kopp HG. Differential changes in platelet VEGF, Tsp, CXCL12, and CXCL4 in patients with metastatic cancer. Clin Exp Metastasis 2010;27(3):141–9.
   PubMed Web of Science ®Google Scholar
• Battinelli EM, Markens BA, Italiano JE, Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: Modulation of physiologic and pathologic angiogenesis. Blood 2011;118(5):1359–1369.
   PubMed Web of Science ®Google Scholar
• Radziwon-Balicka A, Santos-Martinez MJ, Corbalan JJ, O’Sullivan S, Treumann A, Gilmer JF, Radomski MW, Medina C. Mechanisms of platelet-stimulated colon cancer invasion: Role of clusterin and thrombospondin 1 in regulation of the P38MAPK-MMP-9 pathway. Carcinogenesis 2014;35(2):324–332.
   PubMed Web of Science ®Google Scholar
• Klement GL, Yip TT, Cassiola F, Kikuchi L, Cervi D, Podust V, Italiano JE, Wheatley E, Abou-Slaybi A, Bender E and others. Platelets actively sequester angiogenesis regulators. Blood 2009;113(12):2835–2842.
   PubMed Web of Science ®Google Scholar
• Peterson JE, Zurakowski D, Italiano JE, Jr., Michel LV, Connors S, Oenick M, D’Amato RJ, Klement GL, Folkman J. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angiogenesis 2012;15(2):265–273.
   PubMed Web of Science ®Google Scholar
• Peterson JE, Zurakowski D, Italiano JE, Jr., Michel LV, Fox L, Klement GL, Folkman J. Normal ranges of angiogenesis regulatory proteins in human platelets. Am J Hematol 2010;85(7):487–93.
   PubMed Web of Science ®Google Scholar
• McDowell G, Temple I, Li C, Kirwan CC, Bundred NJ, McCollum CN, Burton IE, Kumar S, Byrne GJ. Alteration in platelet function in patients with early breast cancer. Anticancer Res 2005;25(6B):3963–3966.
   PubMed Web of Science ®Google Scholar
• Ma L, Perini R, McKnight W, Dicay M, Klein A, Hollenberg MD, Wallace JL. Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A 2005;102(1):216–20.
   PubMed Web of Science ®Google Scholar
• Italiano JE, Jr., Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J, Klement GL. Angiogenesis is regulated by a novel mechanism: Pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008;111(3):1227–1233.
   PubMed Web of Science ®Google Scholar
• Cooke NM, Egan K, McFadden S, Grogan L, Breathnach OS, O’Leary J, Hennessy BT, Kenny D. Increased platelet reactivity in patients with late-stage metastatic cancer. Cancer Med 2013;2(4):564–570.
   PubMed Web of Science ®Google Scholar
• Boilard E, Nigrovic PA, Larabee K, Watts GF, Coblyn JS, Weinblatt ME, Massarotti EM, Remold-O’Donnell E, Farndale RW, Ware J and others. Platelets amplify inflammation in arthritis via collagen-dependent microparticle production. Science 2010;327(5965):580–583.
   PubMed Web of Science ®Google Scholar
• Gebremeskel S, LeVatte T, Liwski RS, Johnston B, Bezuhly M. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer 2015;136(1):234–240.
   PubMed Web of Science ®Google Scholar
• Sarangi S, Pandey A, Papa AL, Sengupta P, Kopparam J, Dadwal U, Basu S, Sengupta S. P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med Oncol 2013;30(2):567.
   PubMed Web of Science ®Google Scholar
• Etulain J, Fondevila C, Negrotto S, Schattner M. Platelet-mediated angiogenesis is independent of VEGF and fully inhibited by aspirin. Br J Pharmacol 2013;170(2):255–265.
   PubMed Web of Science ®Google Scholar
• Holmes CE, Jasielec J, Levis JE, Skelly J, Muss HB. Initiation of aspirin therapy modulates angiogenic protein levels in women with breast cancer receiving tamoxifen therapy. Clin Transl Sci 2013;6(5):386–390.
   PubMed Web of Science ®Google Scholar
• Schneider DJ, Holmes CE, Taatjes-Sommer HS, Sobel BE. Contributions of young platelets and of previously activated platelets to platelet reactivity in patients with coronary artery disease. Thromb Res 2008;121(4):455–462.
   PubMed Web of Science ®Google Scholar